Innate Pharma 2024 Financial Calendar
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today released its 2024 financial calendar: March 21, 2024: Publication of 2023 financial statements May 14, 2024...
Innate Pharma announces abstracts selected for ESMO congress 2023
Sanofi’s ongoing SAR’579/IPH6101 Phase 1/2 trial in hematologic malignancies selected for oral presentation Presentations under the AstraZeneca collaboration include an IPH5201 early lung cancer Trial...
Number of shares and voting rights of Innate Pharma as of October 3, 2023
Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “ AMF ”) General Regulation...
Innate Pharma provides update on lacutamab clinical program
Phase 2 TELLOMAK trial fully recruited, final data expected Q4 2023 Phase 1b PTCL trial awaiting futility interim analysis, preliminary data expected Q4 2023 US FDA places lacutamab IND on partial...
Cascone et al, 2023.
Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase 2 NeoCOAST Platform Trial
Cancer discovery
Innate Pharma announces encore presentation of interim results of Phase 2 TELLOMAK study with lacutamab with updated Olsen 2022 criteria at the EORTC cutaneous lymphoma tumour group annual meeting 2023
Efficacy results, analyzed according to updated lymph node involvement classification, confirm clinical activity and favorable safety profile of lacutamab in advanced Mycosis Fungoides Updated global...
Innate Pharma Reports First Half 2023 Financial Results And Business Update
Phase 1/2 dose escalation safety and preliminary efficacy of ANKET ® NK cell engager, SAR'579/IPH6101, developed by Sanofi, showed it was well tolerated with observed clinical benefit in patients with...
Innate Pharma announces its participation to upcoming investor conferences and conference call for First half 2023 business update
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that members of its senior management team are scheduled to participate in upcoming investor...
Innate Pharma to participate in upcoming investor conference
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that members of its senior management team are scheduled to participate in the following upcoming...
First patient dosed in SAR’514 / IPH6401 Phase 1/2 clinical trial in relapsed/refractory multiple myeloma
Partner Sanofi advances SAR’514 / IPH6401, a trifunctional anti-BCMA NKp46xCD16 NK cell engager from a joint research collaboration between Innate Pharma and Sanofi, to first-in-human clinical trial...